Salvage Therapies For Radiorecurrent Prostate Cance - Radiorekürren Prostat Kanseri Için Salvage Terapiler

mmustafa's picture
Journal Title, Volume, Page: 
Turkish Journal of Urology 2011; 37(4): 350-356, doi:10.5152/tud.2011.067
Year of Publication: 
2011
Authors: 
Mahmoud Othman Mustafa
University of Texas, MD Anderson Cancer Center, Department of Urology, Surgery Division, Houston, Texas, USA
Current Affiliation: 
Department of Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
Louis L. Pisters
University of Texas, MD Anderson Cancer Center, The Department of Urology, Surgery Division, Houston, Texas
Preferred Abstract (Original): 

Locally recurrent prostate cancer after radiation therapy, also known as radiorecurrent prostate cancer, has an unfavorable prognosis. Two-thirds of patients with radiorecurrent prostate cancer have an advanced pathological disease status by the time they undergo salvage therapy. Several salvage therapies for radiorecurrent prostate cancer are available. Salvage radical prostatectomy (SRP) and salvage cryoablation are the most feasible and effective therapies for radiorecurrent prostate cancer. Although SRP is technically more difficult and has a higher complication rate than do other salvage therapies, the procedure provides a long-term survival benefit. Preliminary studies of salvage robot-assisted radical prostatectomy (SRARP) suggest that SRARP may be similar to or at least as effective as SRP. The intermediate oncological efficacy and morbidity of salvage cryoablation are similar to those of SRP. Prognostic factors for successful salvage therapy include serum prostate-specific antigen level ≤10 ng/mL, Gleason score ≤8, and a clinical disease stage T1c or T2. Assessing the comparative oncological efficacy and complications of the available salvage therapies for radiorecurrent prostate cancer requires strict guidelines, including universal patient selection criteria and an intergrade definition of biochemical failure.

AttachmentSize
Salvage_therapies_for_radiorecurrent_prostate_cance_Radiorekürren_prostat_kanseri_için_salvage_terapiler.pdf281.39 KB